Zealand Pharma released Phase 2 data for petrelintide, an amylin analog that drew one of the industry’s largest obesity partnerships last year. The company reported mean weight reductions up to 10.7% in the trial, results that underpinned the large licensing deal and reinforced amylin biology as a valid metabolic target. The data provide a clinical benchmark for amylin analogs competing with GLP‑1 and dual‑agonist programs, and they prompted Roche and other partners to advance large‑scale development and commercialization plans. Zealand’s readout clarifies dose‑response and safety in humans and will shape regulatory and commercial positioning for amylin‑based weight‑loss medicines. Investors and partners will watch how petrelintide’s efficacy and tolerability compare with tirzepatide and semaglutide derivatives as companies negotiate pricing, payer access, and combination strategies. The Phase 2 results also feed ongoing debates over long‑term durability and the role of combination regimens in obesity pharmacotherapy.